Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01625234
Recruitment Status : Completed
First Posted : June 21, 2012
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
Xcovery Holding Company, LLC